The Trump administration is finalizing a deal with Eli Lilly and Novo Nordisk to offer low-dose versions of Wegovy and Zepbound for $149 per month through TrumpRx, according to a report by the Wall Street Journal on Tuesday.
This agreement would expand Medicare and Medicaid coverage for obesity treatments, marking a first for these GLP-1 drugs.
President Trump is expected to announce the deals on Thursday at the White House, alongside pharmaceutical executives. If approved by the FDA, Eli Lilly’s experimental oral pill, orforglipron, may also be included in this initiative.
These discussions are part of the administration’s “most favored nation” policy aimed at lowering drug prices in the U.S., following similar agreements with Pfizer and AstraZeneca.
The goal is to make effective weight-loss treatments more affordable for millions, particularly seniors, while utilizing government purchasing power to reduce costs from their current levels of over $1,300 per month.
Administrator and Writer
